Trademark Overview
On Tuesday, March 10, 2026, a trademark application was filed for RESILIOME with the United States Patent and Trademark Office. The USPTO has given the RESILIOME trademark a serial number of 79448229. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, April 16, 2026. This trademark is owned by Alchemab Therapeutics Ltd. The RESILIOME trademark is filed in the Chemical Products, Pharmaceutical Products, Computer & Software Products & Electrical & Scientific Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Scientific and technological services; research and development services; research and development services in the field of antibodies and antibody technology; drug development services; drug discovery services; drug development and discovery services in relation to pharmaceutical preparations incorporating antibodies and antibody technology; antibody discovery and identification services; antibody discovery services for the purpose of drug discovery; research in the field of biomarkers; research and development in the field of pharmaceuticals; research and development in the field of diagnostic preparations; clinical research; clinical trials; development and testing of computing methods, algorithms and software in biotechnology and medical fields, including antibody technology; development and testing of computing methods, algorithms and software for the testing and identification of antibodies; development and testing of computing methods, algorithms and software relating to the dev...
Pharmaceutical preparations; medicines for human purposes; pharmaceutical preparations incorporating antibodies for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; chemical preparations for medical and pharmaceutical purposes; pharmaceutical preparations incorporating antibody technology for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; chemical preparations for medical and pharmaceutical purposes incorporating antibodies for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and d...
Downloadable software for the testing of antibodies; downloadable software for the identification of antibodies; downloadable software for use in development of pharmaceutical preparations incorporating antibodies; downloadable software for use in development of pharmaceutical preparations incorporating antibody technology.
Medical testing for diagnostic or treatment purposes; medical diagnostic services; medical analysis for diagnostic and treatment purposes; medical testing, analysis and diagnostic services in the field of antibodies and biomarkers; medical diagnostic services involving the testing of antibodies for medical purposes; analysis and identification of antibody data for medical and diagnostic purposes; information, advisory and consultancy services in relation to all of the aforesaid.
Chemical preparations for scientific or research purposes, other than for medical use; antibodies for scientific or research purposes, other than for medical use; diagnostic preparations for scientific or research purposes, other than for medical use.
